English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance Moxetumomab pasudotox is a fusion protein of an anti-CD22 Fv andPseudomonas exotoxin. It is highly active against leukemia in vitro but acute lymphoblastic leukemia (ALL) patients often are resistant. Studies with cultured cells showed resistance is caused by reduced diphthamide, the intracellular target ofPseudomonas exotoxin, but diphthamide is not reduced in most cells from most ALL patients. To study how resistance develops in animals, we injected ALL cells into mice and found that resistant cells occur in discrete bone marrow niches and contain major chromosomal and transcriptional changes. Mice pretreated with 5-azacytidine show greatly improved responses, supporting a trial of the combination in leukemia patients.

5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox